Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors
CAR-M is a therapy that begins with the isolation of primary monocytes from a patient’s blood, which are then modified with the desired antigen-specific chimeric receptor, such as anti-HER2. The resulting CAR-M modified cells are cryopreserved and will be reinjected into the patient. CAR-Ms may be able to reach immunologically “cold” tumors to activate them […]
